L&G Pharma Breakthrough UCITS ETF (AMS:BIOT)

Netherlands flag Netherlands · Delayed Price · Currency is EUR
11.83
-0.02 (-0.19%)
Last updated: May 12, 2026, 9:04 AM CET
Assets16.38M
Expense Ratio0.49%
PE Ratio18.84
Dividend (ttm)n/a
Dividend Yieldn/a
Ex-Dividend Daten/a
Payout Frequencyn/a
Payout Ration/a
1-Year Return+28.32%
Volume1
Open11.79
Previous Close11.86
Day's Range11.79 - 11.83
52-Week Low8.98
52-Week High12.20
Betan/a
Holdings41
Inception DateJan 23, 2018

About BIOT

BIGT.L was created on 2018-01-23 by L&G . The fund's investment portfolio concentrates primarily on health care equity. The L&G Pharma Breakthrough UCITS ETF (the Fund) is an exchange traded fund (ETF) that aims to track the performance of the Solactive Pharma Breakthrough Value Index Net Total Return (the Index) subject to the deduction of the ongoing charges and other costs associated with operating the Fund.

Asset Class Equity
Category Health Care
Stock Exchange Euronext Amsterdam
Ticker Symbol BIOT
Provider L&G
Index Tracked Solactive Pharma Breakthrough Value Index

Performance

BIOT had a total return of 28.32% in the past year, including dividends. Since the fund's inception, the average annual return has been 4.74%.

Top 10 Holdings

32.50% of assets
NameSymbolWeight
Travere Therapeutics, Inc.TVTX4.01%
LG Chem, Ltd.0519103.39%
Pharma Mar, S.A.PHM3.23%
Jazz Pharmaceuticals plcJAZZ3.22%
Mirum Pharmaceuticals, Inc.MIRM3.19%
Zevra Therapeutics, Inc.ZVRA3.18%
Ultragenyx Pharmaceutical Inc.RARE3.15%
Sarepta Therapeutics, Inc.SRPT3.10%
United Therapeutics CorporationUTHR3.03%
PTC Therapeutics, Inc.PTCT3.01%
View More Holdings